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engagement with engineered 
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antibody single domains fused to 
pro-caspase3
Jennifer s. Chambers1, tim Brend1,2 & terence H. Rabbitts  1
Many tumour causing proteins, such as those expressed after chromosomal translocations or from point 
mutations, are intracellular and are not enzymes per se amenable to conventional drug targeting. We 
previously demonstrated an approach (Antibody-antigen Interaction Dependent Apoptosis (AIDA)) 
whereby a single anti-β-galactosidase intracellular single chain Fv antibody fragment, fused to inactive 
procaspase-3, induced auto-activation of caspase-3 after binding to the tetrameric β-galactosidase 
protein. We now demonstrate that co-expressing an anti-RAs heavy chain single VH domain, that binds 
to mutant RAs several thousand times more strongly than to wild type RAs, with a complementary 
light chain VL domain, caused programmed cell death (pCD) in mutant RAs expressing cells when each 
variable region is fused to procaspase-3. The effect requires binding of both anti-RAS variable region 
fragments and is RAS-specific, producing a tri-molecular complex that auto-activates the caspase 
pathway leading to cell death. AIDA can be generally applicable for any target protein inside cells by 
involving appropriate pairs of antigen-specific intracellular antibodies.
While the search for small molecule drugs to intracellular targets continues, a variety of macromolecules have 
been developed (we collectively refer to macromolecules of this type as macrodrugs1 to discriminate them 
from conventional drugs) that bind to intracellular target proteins and protein complexes to ablate function. 
For instance, antibody fragments targeting the T cell acute leukaemia protein LMO22–4 or macrodrugs tar-
geting RAS proteins that include whole antibodies5, antibody fragments6 and non-antibody formats such as 
DARPins7 have been developed. While intracellular antibodies are very effective inhibitors of protein func-
tion and of protein-protein interactions (PPIs) either as single chain Fv (scFv) or single domain formats, they 
require prolonged expression to sustain an anti-tumour effect, such as shown for anti-RAS intracellular antibody 
fragments6,8. This is because these macromolecules normally have no intracellular effector function to aid cell 
destruction, unlike normal (extracellular) antibodies that can recruit further immune system support through 
their constant (C) regions. In order to achieve a cell killing outcome, entities (equivalent to whole antibody effec-
tors) must be added to the intracellular antibodies.
Several functionalities have been fused to intracellular antibodies to incorporate the equivalent of C-region 
effector functions when operating in cells (reviewed in9). In this context, induction of cell death by intracellular 
antibody binding is an attractive option because antibody binding would ideally induce this biological response. 
Apoptosis, or programmed cell death (PCD), is a normal but tightly controlled process required for cellular turno-
ver, development and correct immune functioning10. Induction of apoptosis is mediated through activation of ini-
tiator caspases and completed by executioner caspases, such as caspase-3. The experimental homo-dimerization 
of procaspase-3 has been shown to permit self-activation and result in apoptosis of cells11,12. Using a model 
system of the naturally homo-tetrameric protein β-galactosidase and its binding by an scFv13, we showed that 
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fusing the scFv to procaspase-3 resulted in antigen-dependent apoptosis due to dimerization of the scFv and 
auto-activation of procaspase-314. The AIDA approach thus requires two adjacent binding antibody fragments to 
bring two procaspase-3 entities together for the auto-activation and the scFv bound to β-galactosidase achieves 
that because of β-galactosidase tetramerization. Normally, intacellular protein multimerization will not occur, 
or will not occur in a way that causes scFv dimers to locate close enough to trigger procaspase auto-activation. 
It was, therefore, necessary to evaluate if a trimeric antigen-antibody fragment protein-protein interaction (i.e. 
VH, VL and antigen) would elicit AIDA. Following optimization of intracellular expression of the domain anti-
bodies and the subsequent development of complementary, antigen-specific VL screening methods, we found 
anti-RAS single light chains that could couple with a potent anti-RAS VH single domain, that binds to mutant 
RAS several thousand times better than to wild type RAS6, to form an Fv. By employing one of these VL that only 
binds to RAS when in the presence of the VH15 we were able to re-evaluate the AIDA system to develop the strat-
egy of antigen-dependent apoptosis that requires the simultaneous binding of VH and VL-procaspase3 fusion 
antibodies in cells. We have used separated VH and VL from an anti-RAS scFv, to show that complementary 
binding of intracellular VH and VL, each fused to procaspase-3, can kill cells expressing mutant RAS. Anti-RAS 
VH-procaspase-3 or VL-procaspase-3 alone do not induce apoptosis. The AIDA method can therefore be adapted 
to kill cancer cells expressing any specific target antigen when suitable complementary pairs of variable region 
antibody fragments are selected.
Results
Induced apoptosis by targeting RAS with two domain antibody-procaspase-3 fusions. We have 
previously identified two separate, intracellular single domain antibodies (iDAbs, one heavy chain and one light 
chain variable region from an scFv that was selected using Intracellular Antibody Capture (IAC)16 against the 
mammalian oncogenic protein RAS6. We have engineered plasmids illustrated in Fig. 1A to express each iDAb 
fused at the carboxy terminal end with the inactive procaspase-3. Three tetracycline-inducible plasmids were pro-
duced, either coding for the anti-VH-proCASP3 or for VL-proCASP3 or a co-expression of both VH-proCASP3 
and VL-proCASP3 (herein referred to as VH-proCASP3 + VL-proCASP3). Each plasmid was stably transfected 
into the human fibrosarcoma cell line HT1080 (that expresses NRASQ61K mutant) and that have previously 
been developed to express the reverse tetracycline transactivator protein (rtTA)8 (these cells are referred to as 
HT1080TetOn or parent cells). We used the synthetic tetracycline, doxycycline, to induce iDAb-proCASP3 plas-
mid expression of the VH-proCASP3 and VL-proCASP3 fusions (confirmed by Western blot with anti-FLAG tag 
(the iDAb tag) and anti-caspase-3; Supplementary Fig. 1). The cells were induced with doxycycline for 48 hours 
and active caspase-3 was demonstrated by incubation with the cell permeable fluorogenic caspase-3 protease sub-
strate PhiPhiLux (Fig. 1B). Cells in which both anti-RAS VH-proCASP3 + VL-proCASP3 were activated showed 
high levels of caspase-3 relative to cells only expressing VH-proCASP3 or VL-proCASP3, consistent with the 
active caspase-3 coming from the formation of VH-proCASP3 and VL- proCASP3 dimers at the RAS protein 
surface and thereby auto-activation of the dimerized procaspase-3.
Apoptosis was confirmed by flow cytometry analysis of doxycycline-induced cells using 7-aminoactinomyc 
in D (7-AAD, which stains the DNA of cells with damaged membranes) and annexin V detection of phosphati-
dylserine (following its deregulated translocation to the outer leaflet of the cell membrane during the initial 
stages of apoptosis). Figure 1C shows that about half of the cells expressing VH-proCASP3 + VL-proCASP3 
are double positive for 7-AAD and annexin V whereas numbers in doxycycline-induced VH-proCASP3-only 
cells are close to those uninduced VH-proCASP3 + VL-proCASP3 cells. Treatment of doxycycline-induced 
VH-proCASP3 + VL-proCASP3 cells with the caspase-3 inhibitor Z-FMK-DEVD17 reduced the 
7-AAD-annexin-V double positive population by about 60% yet little discernable effect on the profile of the 
doxycycline-induced VH-proCASP3-only cells (Fig. 1C). The viability of cells following iDAb expression 
was assessed over three days with each transfected cell type and the parent HT1080TetOn cells (Fig. 1D). 
Treatment of cells with doxycycline had essentially no effect on the viability of the parent cell clones nor in 
ones expressing VL-proCASP3 but substantial loss of viability was observed in three clones expressing 
VH-proCASP3 + VL-proCASP3, consistent with the RAS-VH-VL interaction activating fused procaspase-3. 
Clones expressing VH-proCASP3 alone show some loss of viability, consistent with previous data on the effect of 
the interaction of the RAS-binding iDAb on tumour growth8.
As validation, we further employed the caspase-3 inhibitor Z-FMK-DEVD to assess the role of the 
VH-procaspase-3 and VL-procaspase-3 in the cell killing by carrying out a dose response effect of caspase-3 inhi-
bition by Z-FMK-DEVD in a clone of VH-proCASP3 + VL-proCASP3 and a clone of VH-proCASP3-only cells. 
The viability loss of the VH-proCASP3 + VL-proCASP3 clone was protected with increasing concentration of 
Z-FMK-DEVD (Fig. 1E), supporting the conclusion that these cells die because co-expressing anti-RAS VH and 
VL fused to procaspase-3 invokes exogenous caspase-3 activation in cells. Conversely, the VH-proCASP3-only 
cell viability was not affected by the inhibitor (Fig. 1F), implying that the cell killing effects are mediated by inter-
fering with RAS-effector PPI as previously shown6,8,18. Morphological analysis of cells with induced expression of 
VH-proCASP3 plus VL- proCASP3 showed characteristics of PCD (Supplementary Fig. 2A) with cells rounding 
up, losing membrane definition and detaching from the culture surface within 18–24 hours while those express-
ing only VH-proCASP3 or VL- proCASP3 were not affected (Supplementary Fig. 2B,C respectively).
Apoptosis depends on both VH and VL antibody fragments binding to antigen. Our data show 
that co-expressing anti-RAS VH- and VL- linked to procaspase-3 results in cell death by apoptosis. The anti-RAS 
antibody fragment, RAS antigen and exogenous caspase-3 dependency was confirmed using modified forms of 
the expressed proteins. A luciferase reporter assay was devised to ensure that AIDA requires both VH-proCASP3 
and in VL-proCASP3 binding RAS and is not due to antigen-independent interaction between the β-strands of 
the VH and VL19. HEK293T cells transfected with G5-luc (a Firefly luciferase (Fluc) reporter with GAL4 DNA 
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Figure 1. Activation of apoptosis by anti-RAS iDAb-procaspase3 fusion proteins. A schematic diagram of the 
AIDA expression plasmids (using the tetracycline-inducible pUHD10 plasmid) controlled by the tetracycline 
operator (tet-promoter) is shown in panel (A). Each expressed protein has an amino terminal farnesylation 
signal followed by a FLAG-tag and the iDAb (VH or VL) fused to pro-caspase-3 followed by a viral F2A 
sequence and a HA-tag. In the bottom line, the protein is a fusion of VH-proCASP3 and VL-proCASP3 (VH-
proCASP3 + VL-proCASP3). Mutant clones were also made with mutant VH and mutant caspase-3. The 
activation of caspase-3 was assayed using PhiPhiLux fluorogenic substrate (panel B). Clones of each type, 
including the parent HT1080TetOn line, were cultured in doxycycline for 48 hours and incubated with substrate 
and analyzed by flow cytometry. Blue = cells without doxycycline; red = cells with doxycycline. In panel C, cells 
carrying VH-proCASP3 + VL-proCASP3 or VH-proCASP3 were treated with and without doxycycline, and 
with both doxycycline plus caspase-3 inhibitor (Z-FMK-DEVD, at 40 μM) for 48 hours and apoptotic status 
compared by flow cytometry with Annexin-V and 7-AAD. The numbers refer to cell numbers in each indicated 
quadrants. Panel D shows averaged viability analysis of three clones from each stable cell type (clones A–C) with 
or without doxycycline induction measured over three days using the Prestoblue (Invitrogen) resazurin-based 
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binding sites (DBS) and vectors expressing KRASG12V and the anti-RAS iDAb VH, or mutant VH, fused to VP16 
transactivation domain and various VL single domains, fused to the GAL4 DNA binding domain (DBD). When 
anti-RAS VH was co-expressed with the complementary VL2046, we observed transcriptional activation of Fluc 
(Fig. 2; Supplementary Fig. 3). Similar Fluc activation was found with VLI2120 but to a lesser extent. No significant 
activation was observed when we expressed non-relevant VL, that had been selected with LMO2 protein15. The 
importance of the anti-RAS VH was corroborated using a two VH mutants. In one mutant, VH complementarity 
determining region (CDR) mutations resulting in reduced affinity (dematured version, designated VHdm) and 
the second, a mutant (designated VHmut) that no longer binds KRAS6. (The CDR sequences of the three forms 
of the anti-RAS iDAb are shown in Supplementary Table 1). In the luciferase assay, VHdm retains binding to RAS 
when co-expressed with VL204 whilst VHmut has no ability to stimulate luciferase (Fig. 2). These data confirm 
that the tripartite interaction of anti-RAS VH and a complementary VL (such as VL204) with RAS antigen in this 
cell system is necessary for luciferase activation.
The importance of the VH-RAS interaction on the AIDA was further established using the mutant VHs in 
flow cytometry of annexin-V and 7-AAD staining. While uninduced cells show little annexin-V or 7-AAD stain-
ing (Fig. 3A,B, LH panels), induction of VH-proCASP3 + VL-proCASP3 resulted in about two thirds of cells 
displaying both annexin-V and 7-AAD stain and about one third displaying annexin-V only (Fig. 3B, upper RH 
panel). Little apoptosis was seen in cells with induced VH-proCASP3-only or with the dematured VH version 
(VHdm-proCASP3, Fig. 3A, middle two RH panels) or with mutant anti-RAS VH (VHmut-proCASP3-only 
(Fig. 3A lower RH panel). Determining the viability of cultures and levels of active pro-caspase-3 at the same time 
after induction (48 hours) showed that those expressing VH-proCASP3 + VL-proCASP3 were about 50% viable 
(Fig. 3C) and had about 25-fold greater pro-caspase-3 levels than the other induced cell lines (Fig. 3D). Mutating 
the procaspase-3 (introducing catalytic residue mutations21 as single Cys163, designated (CP3mut) or double 
(Cys163 and His121, designated CP3dmut) into the procaspase-3 domains ablated the apoptosis (Fig. 3B lower 
two RH panels).
A hallmark of CASP3 activation is the digestion of genomic DNA at inter-nucleosomal sites. This results from 
CASP3 cleavage of the inhibitor of caspase-activated DNase (ICAD), allowing the caspase-activated DNase (CAD) 
activity to degrade chromosomal DNA. Cell cycle analysis by flow cytometry provides evidence for the occurrence of 
CAD-mediated DNA degradation in the form of a sub-G1 population that is detectable as events occurring below the 
G1 band when cellular DNA is stained with 7-AAD. Analysis of the cell cycle in the VH-proCASP3 + VL-proCASP3 
induced cells compared to control cell lines was carried out using flow cytometry (Fig. 4). When we compared the sta-
tus of parent cells with and without doxycycline induction, we observed very little difference (panel A). Furthermore 
uninduced VH-proCASP3 + VL-proCASP3 cells showed a cell cycle distribution comparable to the parent cells 
(panel B). However, induction of the VH-proCASP3 and the VL-proCASP3 proteins resulted in substantial levels of 
sub-G1 cells (about 45%). The accumulation of the sub-G1 population was ablated in cells induced to express the VH- 
and VL-fused to mutant proCASP3 (panel C), confirming that the apoptosis results from exogenous caspase-3 and 
RAS antigen binding. A sub-G1 population was not observed within induced cells expressing either VH-proCASP3 
only (panel D), VL-proCASP3 only (panel E) or mutated (non-binding) VH-proCASP3 only (panel F). 
Therefore, the sub-G1 cells occurring from induced apoptosis (AIDA) is VH and VL dependent and exogenous 
caspase-3 dependent, as well as RAS antigen dependent.
AIDA causes RAs-antigen dependent cytotoxicity. Since our purpose was to design a method 
for cytotoxicity in tumour cells by dual binding of iDAb fused to inactive caspase-3, we modelled cell killing 
in 2-D and 3-D culture systems. In a cloning assay, cells were plated in three different densities (the plating 
efficiency of the different cell types is shown in Supplementary Fig. 4A) and cultured with or without doxy-
cycline for nine days before colony counting. Colony formation in doxycycline-treated parent cells was nearly 
100% compared untreated cultures (Fig. 5A) whereas there was a near total absence of colonies with induced 
VH-proCASP3 + VL-proCASP3, compared to those uninduced (Fig. 5B). Dematuration of the anti-RAS VH in 
VHdm-proCASP3 + VL-proCASP3 cells showed reduced colony formation compared to the parental control, 
consistent with the lower affinity with which the dematured VH binds to KRAS (Fig. 5C). Further, there was very 
little difference between induced and uninduced cells expressing VH-proCASP3 alone (D), non-binding mutant 
VHmut-proCASP3 (E) or expressing VL-proCASP3 alone (F).
As an alternative assay for cytotoxicity we established a 3-D spheroid colony assay. Tumour spheroids 
formed from the parental line and one VH-proCASP3 + VL-proCASP3 clone were supported in matrigel and 
expanded to approximately 0.5 mm before being grown with or without doxycycline for 18 days and assessed 
for changes in size and viability. The parental cells showed similar kinetics in the presence or absence of doxy-
cycline (Fig. 5G). By contrast, the doxycycline induced VH-proCASP3 + VL-proCASP3 spheroids did not grow 
at all (Fig. 5H) while the uninduced VH-proCASP3 + VL-proCASP3 spheroids continued to grow. The average 
viability of VH-proCASP3 + VL-proCASP3 spheroids remaining after doxycycline-induced expression of the 
AIDA constructs were minimal (with fluorescence readings barely above background) compared with that of 
the non-doxycycline treated cells (Supplementary Fig. 4B). The cytotoxicity only occurs in the dual VH and VL 
expressing cells.
reagent. Red bars are with and blue bars are without doxycycline. The dose response to the inhibitor, Z-FMK-
DEVD, was measured over a range of concentrations to 40 μM with cells grown for 48 hours, in the presence or 
absence of doxycycline and with and without inhibitor. VH-proCASP3 + VL-proCASP3 cells (panel E) and VH-
proCASP3 only cells (panel F). Error bars in graphs shown in panels (D–F) represent standard deviation from 
the mean.
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Discussion
AIDA can convert cytostatic macrodrugs to cytotoxic ones. Our previous work showed that scFv 
linked to procaspase-3 would self-activate caspase-3 when binding to a tetrameric target protein14. We now 
show that interaction of separated VH and VL, each fused to procaspase-3, will incur a similar self-activation 
caspase-3. We used NRAS as our test target antigen and apoptosis was induced by VH and VL, each fused to pro-
caspase-3 while the individual VH- procaspase-3 or VL- procaspase-3 fusion did not cause apoptosis. Therefore 
the cell death depends on an antigen interaction by both V-region domains fused to procaspase-3. The dimeri-
zation of RAS protein in cells occurs at the plasma membrane22 but we found no evidence that the single VH or 
VL-procaspase-3 protein cause cell death. This is presumably because the spatial arrangement of a potential quad-
rameric complex of RAS-iDAb-procaspase-3/RAS-iDAb-procaspase-3 precludes procaspase-3 dimerization.
The use of the RAS intracellular antibody system was implemented here to show that AIDA can be performed 
with separate VH and VL to yield a ternary complex of antigen, VH and VL wherein the antigen dimerization 
status is not problematic. Could anti-RAS AIDA be therapeutically useful given the ubiquitous expression of RAS 
proteins? In initial experiments using the anti-RAS intracellular antibody, we found that it halted tumour growth 
in xenografted human cancer tumours8. When intracellular antibody induction was stopped, tumour growth 
re-started. Addition of inactive procaspase-3 to anti-RAS VH and VL converts binding into a cytotoxic effect. 
Even though the intracellular antibody binds to mutant RAS to a much greater efficiency in cells than to wild type 
RAS6, it would be mandatory for in vivo use to have an exquisitely tumour-specific delivery option and that does 
not exist as yet.
AIDA technology can be adapted to any target in disease cells. This method can be adapted to any 
target protein inside cells and can be extended to any internal antigen for which two intracellular antibody frag-
ments can be selected or are available with complementary binding sites on the antigen. Thus, it could be widely 
applicable to any tumour-specific protein, including chromosomal translocation fusion protein products where 
iDAbs binding near each other, but traversing the fusion junction could be selected. It may also be possible to 
adapt the method to target two members of a protein complex.
The AIDA method could also be altered for use with other intracellular macrodrugs including DARPins23 and 
peptide aptamers24. Further, while we have used a VH and VL pair in this concept study, it is possible to adapt to 
VH-VH or VL-VL pairs. The key to the functionality of this tertiary system is antigen-specificity of the binding 
partners and antigen-dependent caspase activation. In order to maximize optimization, further adaptations could 
be developing engineered procaspase-3 domains with decreased potency25. Further, it is important that intrinsic 
non-antigen-associated interaction of VH and VL does not cause procaspase-3 activation per se. With this in 
mind, in future it may be beneficial to engineer framework mutations into the VH and VL sequences to minimize 
any untoward macrodrug self-activation.
Macrodrugs, such as the engineered iDAbs needed for AIDA, will not enter cells per se because they are 
proteins. For the use of macrodrugs in general, methods for delivering them to cells in vivo are being developed. 
Recent work shows promise for cell targeting and delivery technologies26 and using mRNA for expression of pro-
teins has been described27,28. We have developed a new lipid nanoparticle (LNPLH) that can encapsulate mRNA 
and deliver to a variety of cells29 that can potentially be developed into a delivery vehicle for cancers to facilitate 
Figure 2. VH and VL iDAb bind to RAS in tertiary complex to induce apoptosis. Luciferase assay of HEK293T 
cells transiently co-transfected with plasmids encoding mutant KRASG12V antigen, various indicated VH-VP16 
and VL-Gal4DBD in addition to Renilla luciferase and a Firefly luciferase reporter plasmid pG5-Luc. The 
expressed anti-RAS VH-VP16 fusion proteins were wild type VH, lower affinity, dematured (called VHdm) 
and mutant (called VHmut) and represented by red, blue and green respectively. Transfections included the 
anti-RAS VL (VL204) and four non-relevant VLs; VLI21 (non specific) and the anti-LMO2 VL domains VL819, 
VL826 and VL827. Triplicate wells were assayed 48 hours post-transfection with the Dual-Glo Luciferase 
reporter reagent (Promega) to assess formation of active transcription complexes. Data was analysed by 
calculation of the Firefly:Renilla luciferase ratio and used to derive the fold luciferase activity relative to the 
empty vector control. Error bars represent the standard deviation from the mean.
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Figure 3. Effect of mutations of VH and caspase-3 on AIDA response. One clone of each type was grown 
for 48 hours, with and without doxycycline and analyzed for induction of apoptosis by flow cytometry with 
Annexin-V (FITC) and 7-AAD (Panels A,B). Panel (A) shows the effect of the VH mutations in the single 
vectors, whilst panel B shows the effect of VH and CASP3 mutations is to reduce induction of apoptosis in 
VH-proCASP3 + VL-proCASP3 expressing cells. The viability (panel C) and caspase-3 activity status (panel 
D) of these clones was judged after 48 hours using the ApoToxGlo (Promega) combined assay in the presence 
(red bars) or absence (blue bars) of doxycycline. Viability measurements were averaged and converted to a 
percentage value for comparison between clone types. Caspase-3 activation was determined by the increase in 
luminescence following cleavage of a reporter peptide. Data were converted to fold activation value, with no 
doxycycline readings given a nominal value of 1 to allow comparison between clone types. Error bars on graphs 
in C and D represent standard deviation from the mean.
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the co-expression the iDAb-proCASP3 proteins. It will be important in addition to confer cell-selectivity on the 
delivery vehicles to ensure normal cells are not influenced by the AIDA reagents if the target protein is present. 
Application of these technologies should bring the AIDA technology into clinical use.
Materials and Methods
Vector construction. A Hygromycin resistance cassette under control of a PGK promoter was inserted into 
pUHD10-3 plasmid to create pUHD10-3H. Insertion of synthesized oligos (Sigma) created a modified multiple 
cloning site for downstream cloning, and subsequently FLAG and HA tags and the F2A site were amplified by 
PCR using Phusion polymerase (New England BioLabs) and ligated. VH- (#Y6)30 and variants, and VL- (#204)15 
procaspase-3 fusions were also amplified PCR amplified and cloned either singly or sequentially in the case of the 
co-expressing VH and VL vector. Later an N-terminal farnesylation signal derived from Neuromodulin/GAP43 
was added to create membrane-targeted constructs. Procaspase-3 catalytic mutations (C163S and H121G) were 
introduced by PCR mutagenesis, and subsequently sub-cloned into the vectors.
Cell culture and DNA transfection. HT1080 cells expressing the reverse Tetracycline transactivator31 
(referred to as HT1080TetOn or Parental) were cultured in DMEM with Glutamax (Gibco) and supplemented 
with 10% FBS (Sigma) and Penicillin/Streptomycin (Gibco) and incubated at 37 °C, 5% CO2. 4 × 105 Cells were 
transfected in one well of a 6-well plate, with 3 μg of SpeI-linearized plasmid and 10 μl Lipofectamine 2000 
(Invitrogen) in a total volume of 1 ml Optimem (Gibco) for 3–5 hrs. Medium was replaced and cells split at 48 hrs 
post-transfection and replated onto 10 cm dishes. Antibiotic selection was applied 72 hrs post-transfection, with 
500 μg/ml G418 (Gibco) and 200 μg/ml Hygromycin B (Invitrogen). Selective medium was replaced every two 
days for approximately 7–12 days, until the control (untransfected) plate was devoid of cells. Resulting colonies 
were picked, propagated and screened by Western blot. Induction of doxycycline-inducible transgene expression 
was performed with 1 μg/ml doxycycline Hyclate (Sigma) on cells plated at an initial density of 2 × 104/cm2.
Western blot analysis. After 48 hrs of doxycycline induction, 10 μg total protein was boiled for 5 mins in 
Laemmli buffer (125 mM Tris pH6.8, 5% β-Mercaptoethanol, 2% SDS, 10% Glycerol, 0.002% Bromophenol Blue). 
Samples were loaded per lane onto SDS-PAGE gels alongside 3 μl BluEye Prestained protein ladder (GeneFlow). 
Gels were transferred to PVDF membrane (GE Healthcare) at 350 mA for 1 hr. Membranes were blocked in TBS-T 
buffer (1x TBS (Severn Biotech), 0.1% v/v Tween-20 (Sigma)) containing 5% non-fat milk powder for 1 hr at 
Figure 4. Effect of the AIDA on cell cycle progression. The effect of expressing the VH/VL-proCASP3 proteins 
and their variants on the cell cycle was assessed by flow cytometry. Cells were induced for 48 hours, fixed, 
permeabilized, and stained with 7-AAD. Live, single cells were gated according to their size and granularity by 
forward and side scatter parameters. The normal cell cycle populations (G0/G1, S and G2/M phases) were set 
on the uninduced Parental cell line. Data are represented as overlaid histograms, with the cell cycle gates shown 
on each plot. The regions for subG1, G1, S and G2 + M phases are indicated. Blue trace = uninduced cells Red 
trace = tetracycline induced cells.
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room temperature. Primary antibodies were incubated in TBS-T with 1% milk as follows; M2 anti-FLAG (Sigma), 
anti-CASP3 and anti-HA tag (both Cell Signaling), were used at 1:1000 dilution, β-Actin (Sigma) at 1:4000 dilu-
tion, with all incubated at 4 °C overnight. Secondary HRP-linked antibodies (anti-mouse and anti-rabbit, both 
Cell Signaling) diluted 1:1000 in TBS-T with 1% milk were applied for 1 hr at room temp. Blots were incubated 
with ECL reagent (Pierce) and developed on film (Sigma) with X-O-Graph developer system.
PhiPhiLux CASP3 activity. At 48 hrs post-doxycycline induction, 5 × 105 cells per growth condition were 
pelleted at 200 × g, 5 min at room temperature and resuspended in at total volume of 83 μl (comprising 75 μl 
PhiPhiLux reagent and 8 μl FBS), and incubated for 30 min at 37 °C. Cells were washed in 1 ml PhiPhiLux buffer 
Figure 5. Cytotoxicity caused by VH-VL-procaspase3 using in vitro tumorigenicity models. Two types of 
in vitro assays were used to follow cytoxicity following VH-proCASP3 + VL-proCASP3 induction, namely a 
minimal dilution plating clonogenic assay (panels A–F) and a 3-D spheroid assay (panels G,H). In the plating 
assay, up to three clones of each type clones indicated (clones A–C) were plated at 20, 50 or 100 cells per dish (in 
triplicate) and grown for 9 days with and without doxycycline. Cell were fixed and stained with crystal violet for 
visualization. Colonies were graded as foci if they contained ≥10 cells. The bar charts show the averaged colony 
counts for each cell type in the presence of doxycycline (red bars) or absence (blue bars) of doxycycline. Panel 
A. Parental HT1080TetOn line; Panel (B). VH-proCASP3 + VL-proCASP3 clones (A–C); Panel (C). dematured 
VH VHdm-proCASP3 + VL-proCASP3 clones (A–C); Panel (D). VH-proCASP3 clones (A–C); Panel E. mutant 
VH VHmut-proCASP3 clones (A,B); Panel (F). VL-proCASP3 clones (A–C). Statistical significance of the data 
was determined by performing Student T-tests, where significant p values (<0.05) are indicated by the following 
key; *<0.05, **≤0.01 and ***≤0.001, where n = 3 readings per condition. Error bars represent standard 
deviation from the mean. The growth in spheroid development was measured over an 18 day period comparing 
the parent HT1080TetOn line (panel G) with the VH-proCASP3 + VL-proCASP3 clone (panel H). Images were 
taken and area measurements were analyzed by FIJI software34. Error bars represent standard deviation from 
the mean, with n = 4 for all conditions.
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and pelleted as before. Cells were resuspended in buffer and fluorescence measured by flow cytometry on the 
FITC channel of a Cyan ADP analyser (Beckman Coulter). Data was analyzed using FlowJo software (TreeStar).
Annexin V and 7-AAD flow cytometry analysis. At 48 hrs post-doxycycline induction, cells were 
harvested and pelleted at 200 × g for 5 mins, room temperature. 5 × 104 cells were washed and resuspended in 
100 μl in Annexin V buffer (10 mM HEPES pH7.4, 140 mM NaCl, 2.5 mM CaCl2) with 2 μl Annexin V-FITC 
(BD Pharmingen) and stained on ice for 30 mins. Cells were washed and resuspended as before, with 5 μl 7-AAD 
(50 μg/ml, BD Pharmingen) and incubated on ice for 15–20 mins diluted with annexin V buffer immediately 
before collecting fluorescence measurements on an Attune flow cytometer (Invitrogen). Data was analyzed using 
FlowJo software (TreeStar).
Cell cycle analysis. Cell clones were plated in 6-well plates at an initial density of 2 × 104/cm2 in two tripli-
cate sets (for −/+tetracycline) and left to adhere overnight. Growth medium was replaced the following day, and 
induction was performed with 1 μg/ml tetracycline (Sigma Aldrich, Dorset, UK). After 48 hrs cells were harvested 
with 0.05% Trypsin (Gibco, MA, USA) and pelleted at 200 × g for 5 mins at room temperature. 5 × 104 cells were 
washed in PBS, fixed and permeabilized in 2 ml of ice-cold 70% ethanol followed by incubation at −20 °C for at 
least one hour. Cells were pelleted as before, washed twice in PBS and resuspended in 50 μl of 50 μg/ml 7-AAD 
staining solution (BD, New Jersey, USA), supplemented with 0.1% Triton X-100 (Sigma Aldrich, Dorset, UK), 
2.5 units of RNase A (Thermo Scientific, MA, USA). Cellular DNA was stained for 30 mins at room temperature 
while protected from light. Samples were diluted with PBS immediately before collecting area fluorescence meas-
urements on a linear scale with an Attune flow cytometer (Invitrogen, Paisley, UK). Data were analyzed using 
FlowJo software (TreeStar, OR, USA) where cell cycle gates (Sub G1, G1, S and G2/M phases) were set on the 
uninduced (no tetracycline) sample of each clone.
Viability assays. Cells were plated in triplicate at 4 × 104 per well in 24-well culture plates, and protein 
expression was induced with doxycycline as before, for 48 hrs where appropriate. PrestoBlue Viability reagent 
(Invitrogen) was diluted 1:10 in normal growth medium and applied to cells for 20 mins at 37 °C, 5% CO2. 
Fluorescence was measured at 544 nm excitation and 590 nm emission with a Spectramax M2e (Molecular 
Devices) plate reader. Blank (no cell) well readings were averaged and subtracted from all experimental data 
points. Results were converted to a percentage viability relative to the respective clone uninduced reading, to 
allow comparison between clone types.
Caspase-3 inhibitor experiments. Cells were plated in triplicate as before in 24-well culture plates, and 
protein expression was induced with doxycycline for 48 hrs where appropriate. Irreversible CASP3 inhibitor 
Z-DEVD-FMK (Santa Cruz Biotechnology) was reconstituted in DMSO (Sigma) to 20 mM and applied to cells 
over a range of concentrations from 0–40 μM with standard addition of doxycycline. Controls consisted of i) 
uninduced, no inhibitor and ii) induced, no inhibitor wells. All wells were normalized to contain 0.2% v/v DMSO. 
Data was collected and analyzed by Annexin V, 7-AAD flow cytometry and viability assays.
spheroid growth. The method adapted from Cultrex 3-D Spheroid Fluorometric Proliferation/Viability 
assay (Trevigen)32,33. Cells were harvested with 0.05% Trypsin (Gibco, MA, USA) and pelleted at 200 × g for 
5 mins, at room temperature. After counting, cells were kept on ice to ensure they were chilled ready for matrigel 
addition. Cells were washed once in PBS (Gibco), and resuspended in a 1:10 mix of ice-cold matrigel (BD, New 
Jersey, USA) to growth medium at a density of 2 × 104/ml. 50 μl of cell mixture was added to each well of a 
ultra-low adhesion round-bottom 96-well plate (Corning, New York, USA) and centrifuged at 200 × g, 5 mins, 
4 °C. Plates were transferred to a 37 °C, 5% CO2 incubator for 30 mins to allow the matrigel layer to set. Once 
solidified, 50 μl of growth medium was overlaid, with those wells receiving doxycycline beginning treatment 
when spheroids reached ~0.5 mm diameter. Induction of doxycycline-inducible transgene expression was per-
formed with 1 μg/ml tetracycline (Sigma Aldrich, Dorset, UK). Plates were cultured for the next 14 days, with 
light microscope images taken every two days. Extra growth medium was added at regular intervals to avoid 
accidental damage to the spheroids. At the end of the experiment, area changes were calculated using FIJI image 
analysis software34 and spheroid viability was measured using PrestoBlue reagent (Invitrogen, Paisley, UK) as pre-
viously described. Unpaired two-tailed student t tests were performed on the viability assay results and calculated 
by GraphPad Prism 7.0 software (GraphPad Software, CA, USA).
ApotoxGlo (promega) assay. Cells plated in 96-well plates at an initial density of 2 × 104/cm2 with dox-
ycycline induction was performed as before. Etoposide was added to control wells at 100 μM for 8 hrs. Assay 
was measured at 18 and 48 hrs post-Tet addition and performed according to the manufacturer’s instructions. 
Fluorescence and luminescence measurements read by a M2e Spectramax plate reader (Molecular Devices). 
Averaged blank well readings were subtracted from all data points. Results were converted to either percentage 
(Viability) or fold increase (CASP3) relative to the respective clone’s un-induced reading.
Clonal assay. The method was adapted from Franken et al.35. Cells were harvested and pelleted in a bench top 
centrifuge (Eppendorf) at 200 × g for 5 minutes at RT. The supernatant was discarded and cells were resuspended 
in 10 ml of growth medium and viable cells were counted by trypan blue dye exclusion. A working cell suspension 
of 2 × 102 cells/ml for plating was prepared by serial dilution. Appropriate volumes of the working suspension 
were mixed with medium to achieve (i) 20, (ii) 50 and (iii) 100 cells in a total volume of 4 ml per 6 cm diameter 
plate (Corning). Six replica plates were made per cell density to allow triplicate plates of both growth conditions 
(+/−doxycycline). Next day, medium was removed and replaced with either fresh medium (three plates) or 
medium containing 1 μg/ml doxycycline (three plates). Cells were incubated at 37 °C, 5% CO2 for the next nine 
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days, replacing medium every three days (+/−doxycycline). On day nine, the growth medium was removed and 
the cell layer washed with PBS (Gibco). Colonies were stained for 30 minutes with 3 ml staining solution (6% v/v 
glutaraldehyde (Sigma Aldrich), 0.5% w/v Crystal Violet (Sigma Aldrich)). Plates were washed twice with deion-
ized water and finally gently submerged in deionized water to remove the last traces of dye, and left to dry. Cell 
patches of greater than 10 cells were deemed to be a colony for this assay (due to the anticipated growth imped-
ance effect of the anti-Ras VH). Colonies were visualized on a large-field view stereomicroscope (Leica MZFLIII) 
and counted using a colony counting pen (VWR). The Plating Efficiency (PE) of each clone was calculated from 
combined average colony counts of all cell densities tested of the uninduced (no doxycycline) plates.
Luciferase assays. Combinations of VH and VL variants (anti-RAS VH, VHdm and VHmut, anti-RAS 
VL#204, non-specific VL#I21 and anti-LMO2 VLs #819, #826 and #82715) were cloned into the triplex vector16 
via NotI/SfiI and BamHI/EcoRV restriction sites. HEK293T cells were transiently co-transfected in triplicate with 
the 400 ng triplex plasmids encoding the various combinations of both VH-VP16 and VL-Gal4DBD, alongside 
200 ng pG5-Luc reporter and 200 ng pPGK-KRAS166(G12V)-2A-Puro RAS antigen plasmid. Cells were analyzed 
for luciferase activity 48 hours post-transfection using the Dual-Glo Luciferase assay (Promega), with lumines-
cence measurements read by a M2e Spectramax plate reader (Molecular Devices). The ratio of Renilla to Firefly 
luciferase was calculated. Fold luciferase activity was calculated relative to the empty vector control.
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